Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03643549
Title Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) (BORTEM-17)
Acronym BORTEM-17
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Haukeland University Hospital
Indications
Therapies
Age Groups: adult | senior
Covered Countries NOR


No variant requirements are available.